Cardiolipin metabolism and the role it plays in Heart Failure and mitochondrial supercomplex formation

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 2, 2014, Pages 98-106

  Mejia, Edgard M ^a   Cole, Laura K ^a   Hatch, Grant M ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Barth syndrome; Cardiolipin; Heart failure; Mitochondria; Monolysocardiolipinacyltransferase; Phospholipid; Tafazzin

Indexed keywords

1 ACYLGLYCEROPHOSPHOCHOLINE ACYLTRANSFERASE; ACYLGLYCEROL PALMITOYLTRANSFERASE; CARDIOLIPIN; DIHYDROLIPOAMIDE DEHYDROGENASE; PHOSPHOLIPASE A2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SHORT HAIRPIN RNA; STOMATIN; ACYLTRANSFERASE; LYSOPHOSPHOLIPID; MONOLYSOCARDIOLIPIN; MONOLYSOCARDIOLIPIN ACYLTRANSFERASE; TAZ PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; BARTH SYNDROME; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME ACTIVITY; HEART FAILURE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; METABOLIC REGULATION; MITOCHONDRIAL DYNAMICS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; PROTEIN SYNTHESIS; ANIMAL; BIOSYNTHESIS; ENZYMOLOGY; HEART MUSCLE; METABOLISM; MITOCHONDRION; PATHOLOGY;

ACYLTRANSFERASES; ANIMALS; BARTH SYNDROME; BIOSYNTHETIC PATHWAYS; CARDIOLIPINS; HEART FAILURE; HUMANS; LYSOPHOSPHOLIPIDS; MITOCHONDRIA; MYOCARDIUM; TRANSCRIPTION FACTORS;

EID: 84906282354     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529X14666140505123753     Document Type: Article

References (96)

1. White, D.A. Form and function of phospholipids. In: Phospholipids; Ansell, G. B., Hawthorne, J. N. and Dawson, R. M., Eds.; Elsevier Biomedical: 1973.
2. Hostetler, K.Y. Polyglycerophospholipids: phosphatidylglycerol, diphosphatidylglycerol and bis (monoacylglycero) phosphate. In: Phospholipids; Hawthorne, J. N., Ansell, G. B., Eds.; 1982; pp 215.
3. Pangborn, M. Isolation and purification of a serologically active phospholipid from beef heart. J. Biol. Chem., 1942, 143, 247-256.
4. Hovius, R.; Lambrechts, H.; Nicolay, K.; de Kruijff, B. Improved methods to isolate and subfractionate rat liver mitochondria. Lipid composition of the inner and outer membrane. Biochim. Biophys. Acta, 1990, 1021(2), 217-226.
5. Hovius, R.; Thijssen, J.; van der Linden, P.; Nicolay, K.; de Kruijff, B. Phospholipid asymmetry of the outer membrane of rat liver mitochondria. Evidence for the presence of cardiolipin on the outside of the outer membrane. FEBS Lett., 1993, 330(1), 71-76.
6. Stoffel, W.; Schiefer, H.G. Biosynthesis and composition of phosphatides in outer and inner mitochondrial membranes. Hoppe Seylers Z. Physiol. Chem., 1968, 349(8), 1017-1026.
7. Poorthuis, B.J.; Yazaki, P.J.; Hostetler, K.Y. An improved two dimensional thin-layer chromatography system for the separation of phosphatidylglycerol and its derivatives. J. Lipid Res., 1976, 17(4), 433-437.
8. Hatch, G.M. Cell biology of cardiac mitochondrial phospholipids. Biochem. Cell Biol., 2004, 82(1), 99-112.
9. Hoch, F.L. Cardiolipins and biomembrane function. Biochim. Biophys. Acta, 1992, 1113(1), 71-133.
10. Zhang, M.; Mileykovskaya, E.; Dowhan, W. Gluing the respiratory chain together. Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane. J. Biol. Chem., 2002, 277(46), 43553-43556.
11. Reig, J.; Domingo, E.; Segura, R.; Tovar, J.L.; Vinallonga, M.; Borrell, M. Rat myocardial tissue lipids and their effect on ventricular electrical activity: influence on dietary lipids. Cardiovasc. Res., 1993, 27(3), 364-370.
12. Hatch, G.M. Cardiolipin biosynthesis in the isolated heart. Biochem. J., 1994, 297(Pt 1)(Pt 1), 201-208.
13. Tamura, Y.; Harada, Y.; Nishikawa, S.; Yamano, K.; Kamiya, M.; Shiota, T.; Kuroda, T.; Kuge, O.; Sesaki, H.; Imai, K.; Tomii, K.; Endo, T. Tam41 Is a CDP-Diacylglycerol Synthase Required for Cardiolipin Biosynthesis in Mitochondria. Cell. Metab., 2013, 17(5), 709-718.
14. Jiang, Y.J.; Lu, B.; Xu, F.Y.; Gartshore, J.; Taylor, W.A.; Halayko, A.J.; Gonzalez, F.J.; Takasaki, J.; Choy, P.C.; Hatch, G.M. Stimulation of cardiac cardiolipin biosynthesis by PPARalpha activation. J. Lipid Res., 2004, 45(2), 244-252.
15. Ostojic, O.; O'Leary, M.F.; Singh, K.; Menzies, K.J.; Vainshtein, A.; Hood, D.A. The effects of chronic muscle use and disuse on cardiolipin metabolism. J. Appl. Physiol. (1985), 2013, 114(4), 444-452.
16. Osman, C.; Haag, M.; Wieland, F.T.; Brugger, B.; Langer, T. A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4. EMBO J., 2010, 29(12), 1976-1987.
17. Xiao, J.; Engel, J.L.; Zhang, J.; Chen, M.J.; Manning, G.; Dixon, J.E. Structural and functional analysis of PTPMT1, a phosphatase required for cardiolipin synthesis. Proc. Natl. Acad. Sci. USA, 2011, 108(29), 11860-11865.
18. Hostetler, K.Y.; Van den Bosch, H.; Van Deenen, L.L. Biosynthesis of cardiolipin in liver mitochondria. Biochim. Biophys. Acta, 1971, 239(1), 113-119.
19. Hauff, K.D.; Hatch, G.M. Cardiolipin metabolism and Barth Syndrome. Prog. Lipid Res., 2006, 45(2), 91-101.
20. Sparagna, G.C.; Chicco, A.J.; Murphy, R.C.; Bristow, M.R.; Johnson, C.A.; Rees, M.L.; Maxey, M.L.; McCune, S.A.; Moore, R.L. Loss of cardiac tetralinoleoyl cardiolipin in human and experimental heart failure. J. Lipid Res., 2007, 48(7), 1559-1570.
21. Lands, W.E. Stories about acyl chains. Biochim. Biophys. Acta, 2000, 1483(1), 1-14.
22. Buckland, A.G.; Kinkaid, A.R.; Wilton, D.C. Cardiolipin hydrolysis by human phospholipases A2. The multiple enzymatic activities of human cytosolic phospholipase A2. Biochim. Biophys. Acta, 1998, 1390(1), 65-72.
23. Mancuso, D.J.; Sims, H.F.; Han, X.; Jenkins, C.M.; Guan, S.P.; Yang, K.; Moon, S.H.; Pietka, T.; Abumrad, N.A.; Schlesinger, P.H.; Gross, R.W. Genetic ablation of calcium-independent phospholipase A2gamma leads to alterations in mitochondrial lipid metabolism and function resulting in a deficient mitochondrial bioenergetic phenotype. J. Biol. Chem., 2007, 282(48), 34611-34622.
24. Seleznev, K.; Zhao, C.; Zhang, X.H.; Song, K.; Ma, Z.A. Calciumindependent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J. Biol. Chem., 2006, 281(31), 22275-22288.
25. Muralikrishna Adibhatla, R.; Hatcher, J.F. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic. Biol. Med., 2006, 40(3), 376-387.
26. Su, H.; McClarty, G.; Dong, F.; Hatch, G.M.; Pan, Z.K.; Zhong, G. Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. J. Biol. Chem., 2004, 279(10), 9409-9416.
27. Hsu, Y.H.; Dumlao, D.S.; Cao, J.; Dennis, E.A. Assessing phospholipase A2 activity toward cardiolipin by mass spectrometry. PLoS One, 2013, 8(3), e59267.
28. Baile, M.G.; Whited, K.; Claypool, S.M. Deacylation on the matrix side of the mitochondrial inner membrane regulates cardiolipin remodeling. Mol. Biol. Cell, 2013, 24(12), 2008-2020.
29. Cao, J.; Liu, Y.; Lockwood, J.; Burn, P.; Shi, Y. A novel cardiolipin-remodeling pathway revealed by a gene encoding an endoplasmic reticulum-associated acyl-CoA:lysocardiolipin acyltransferase (ALCAT1) in mouse. J. Biol. Chem., 2004, 279(30), 31727-31734.
30. Zhao, Y.; Chen, Y.Q.; Li, S.; Konrad, R.J.; Cao, G. The microsomal cardiolipin remodeling enzyme acyl-CoA lysocardiolipin acyltransferase is an acyltransferase of multiple anionic lysophospholipids. J. Lipid Res., 2009, 50(5), 945-956.
31. Li, J.; Romestaing, C.; Han, X.; Li, Y.; Hao, X.; Wu, Y.; Sun, C.; Liu, X.; Jefferson, L.S.; Xiong, J.; Lanoue, K.F.; Chang, Z.; Lynch, C.J.; Wang, H.; Shi, Y. Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity. Cell. Metab., 2010, 12(2), 154-165.
32. Liu, X.; Ye, B.; Miller, S.; Yuan, H.; Zhang, H.; Tian, L.; Nie, J.; Imae, R.; Arai, H.; Li, Y.; Cheng, Z.; Shi, Y. Ablation of ALCAT1 mitigates hypertrophic cardiomyopathy through effects on oxidative stress and mitophagy. Mol. Cell. Biol., 2012, 32(21), 4493-4504.
33. Athea, Y.; Viollet, B.; Mateo, P.; Rousseau, D.; Novotova, M.; Garnier, A.; Vaulont, S.; Wilding, J.R.; Grynberg, A.; Veksler, V.; Hoerter, J.; Ventura-Clapier, R. AMP-activated protein kinase alpha2 deficiency affects cardiac cardiolipin homeostasis and mitochondrial function. Diabetes, 2007, 56(3), 786-794.
34. Schlame, M.; Rustow, B. Lysocardiolipin formation and reacylation in isolated rat liver mitochondria. Biochem. J., 1990, 272(3), 589-595.
35. Ma, B.J.; Taylor, W.A.; Dolinsky, V.W.; Hatch, G.M. Acylation of monolysocardiolipin in rat heart. J. Lipid Res., 1999, 40(10), 1837-1845.
36. Taylor, W.A.; Hatch, G.M. Purification and characterization of monolysocardiolipin acyltransferase from pig liver mitochondria. J. Biol. Chem., 2003, 278(15), 12716-12721.
37. Taylor, W.A.; Hatch, G.M. Identification of the human mitochondrial linoleoyl-coenzyme A monolysocardiolipin acyltransferase (MLCL AT-1). J. Biol. Chem., 2009, 284(44), 30360-30371.
38. Taylor, W.A.; Mejia, E.M.; Mitchell, R.W.; Choy, P.C.; Sparagna, G.C.; Hatch, G.M. Human trifunctional protein alpha links cardiolipin remodeling to Beta-oxidation. PLoS One, 2012, 7(11), e48628.
39. Xu, Y.; Kelley, R.I.; Blanck, T.J.; Schlame, M. Remodeling of cardiolipin by phospholipid transacylation. J. Biol. Chem., 2003, 278(51), 51380-51385.
40. Xu, Y.; Malhotra, A.; Ren, M.; Schlame, M. The enzymatic function of tafazzin. J. Biol. Chem., 2006, 281(51), 39217-39224.
41. Zhuravleva, E.; Gut, H.; Hynx, D.; Marcellin, D.; Bleck, C.K.; Genoud, C.; Cron, P.; Keusch, J.J.; Dummler, B.; Esposti, M.D.; Hemmings, B.A. Acyl coenzyme A thioesterase Them5/Acot15 is involved in cardiolipin remodeling and fatty liver development. Mol. Cell. Biol., 2012, 32(14), 2685-2697.
42. Ferreira, R.; Guerra, G.; Padrao, A.I.; Melo, T.; Vitorino, R.; Duarte, J.A.; Remiao, F.; Domingues, P.; Amado, F.; Domingues, M.R. Lipidomic characterization of streptozotocin-induced heart mitochondrial dysfunction. Mitochondrion, 2013, 13(6):762-71.
43. Yamaoka, S.; Urade, R.; Kito, M. Cardiolipin molecular species in rat heart mitochondria are sensitive to essential fatty acid-deficient dietary lipids. J. Nutr., 1990, 120(5), 415-421.
44. Ohtsuka, T.; Nishijima, M.; Suzuki, K.; Akamatsu, Y. Mitochondrial dysfunction of a cultured Chinese hamster ovary cell mutant deficient in cardiolipin. J. Biol. Chem., 1993, 268(30), 22914-22919.
45. Petrosillo, G.; Ruggiero, F.M.; Paradies, G. Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria. FASEB J., 2003, 17(15), 2202-2208.
46. Hatch, G.M. Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (Review). Int. J. Mol. Med., 1998, 1(1), 33-41.
47. Gonzalvez, F.; Schug, Z.T.; Houtkooper, R.H.; MacKenzie, E.D.; Brooks, D.G.; Wanders, R.J.; Petit, P.X.; Vaz, F.M.; Gottlieb, E. Cardiolipin provides an essential activating platform for caspase-8 on mitochondria. J. Cell Biol., 2008, 183(4), 681-696.
48. Ascenzi, P.; Polticelli, F.; Marino, M.; Santucci, R.; Coletta, M. Cardiolipin drives cytochrome c proapoptotic and antiapoptotic actions. IUBMB Life, 2011, 63(3), 160-165.
49. Christie, D.A.; Lemke, C.D.; Elias, I.M.; Chau, L.A.; Kirchhof, M.G.; Li, B.; Ball, E.H.; Dunn, S.D.; Hatch, G.M.; Madrenas, J. Stomatin-like protein 2 binds cardiolipin and regulates mitochondrial biogenesis and function. Mol. Cell. Biol., 2011, 31(18), 3845-3856.
50. Osman, C.; Haag, M.; Potting, C.; Rodenfels, J.; Dip, P.V.; Wieland, F.T.; Brugger, B.; Westermann, B.; Langer, T. The genetic interactome of prohibitins: coordinated control of cardiolipin and phosphatidylethanolamine by conserved regulators in mitochondria. J. Cell Biol., 2009, 184(4), 583-596.
51. Osman, C.; Merkwirth, C.; Langer, T. Prohibitins and the functional compartmentalization of mitochondrial membranes. J. Cell. Sci., 2009, 122(Pt 21), 3823-3830.
52. van Gestel, R.A.; Rijken, P.J.; Surinova, S.; O'Flaherty, M.; Heck, A.J.; Killian, J.A.; de Kroon, A.I.; Slijper, M. The influence of the acyl chain composition of cardiolipin on the stability of mitochondrial complexes; an unexpected effect of cardiolipin in alpha-ketoglutarate dehydrogenase and prohibitin complexes. J. Proteomics, 2010, 73(4), 806-814.
53. Dudek, J.; Cheng, I.F.; Balleininger, M.; Vaz, F.M.; Streckfuss-Bomeke, K.; Hubscher, D.; Vukotic, M.; Wanders, R.J.; Rehling, P.; Guan, K. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome. Stem Cell. Res., 2013, 11(2), 806-819.
54. Christie, D.A.; Kirchhof, M.G.; Vardhana, S.; Dustin, M.L.; Madrenas, J. Mitochondrial and plasma membrane pools of stomatin-like protein 2 coalesce at the immunological synapse during T cell activation. PLoS One, 2012, 7(5), e37144.
55. Maranzana, E.; Barbero, G.; Falasca, A.I.; Lenaz, G.; Genova, M.L. Mitochondrial Respiratory Supercomplex Association Limits Production of Reactive Oxygen Species from Complex I. Antioxid. Redox Signal., 2013, 19(13),1469-80.
56. Weber, T.A.; Koob, S.; Heide, H.; Wittig, I.; Head, B.; van der Bliek, A.; Brandt, U.; Mittelbronn, M.; Reichert, A.S. APOOL is a cardiolipin-binding constituent of the Mitofilin/MINOS protein complex determining cristae morphology in mammalian mitochondria. PLoS One, 2013, 8(5), e63683.
57. Schlame, M. Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J. Lipid Res., 2008, 49(8), 1607-1620.
58. Houtkooper, R.H.; Vaz, F.M. Cardiolipin, the heart of mitochondrial metabolism. Cell Mol. Life Sci., 2008, 65(16), 2493-2506.
59. Rigaud, C.; Lebre, A.S.; Touraine, R.; Beaupain, B.; Ottolenghi, C.; Chabli, A.; Ansquer, H.; Ozsahin, H.; Di Filippo, S.; De Lonlay, P.; Borm, B.; Rivier, F.; Vaillant, M.C.; Mathieu-Dramard, M.; Goldenberg, A.; Viot, G.; Charron, P.; Rio, M.; Bonnet, D.; Donadieu, J. Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet J. Rare Dis., 2013, 8, 70, 1172-1870.
60. Claypool, S.M.; Whited, K.; Srijumnong, S.; Han, X.; Koehler, C.M. Barth syndrome mutations that cause tafazzin complex lability. J. Cell Biol., 2011, 192(3), 447-462.
61. Houtkooper, R.H.; Rodenburg, R.J.; Thiels, C.; van Lenthe, H.; Stet, F.; Poll-The, B.T.; Stone, J.E.; Steward, C.G.; Wanders, R.J.; Smeitink, J.; Kulik, W.; Vaz, F.M. Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. Anal. Biochem., 2009, 387(2), 230-237.
62. Vreken, P.; Valianpour, F.; Nijtmans, L.G.; Grivell, L.A.; Plecko, B.; Wanders, R.J.; Barth, P.G. Defective remodeling of cardiolipin and phosphatidylglycerol in Barth syndrome. Biochem. Biophys. Res. Commun., 2000, 279(2), 378-382.
63. Schlame, M.; Shanske, S.; Doty, S.; Konig, T.; Sculco, T.; DiMauro, S.; Blanck, T.J. Microanalysis of cardiolipin in small biopsies including skeletal muscle from patients with mitochondrial disease. J. Lipid Res., 1999, 40(9), 1585-1592.
64. Schlame, M.; Towbin, J.A.; Heerdt, P.M.; Jehle, R.; DiMauro, S.; Blanck, T.J. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann. Neurol., 2002, 51(5), 634-637.
65. Brandner, K.; Mick, D.U.; Frazier, A.E.; Taylor, R.D.; Meisinger, C.; Rehling, P. Taz1, an outer mitochondrial membrane protein, affects stability and assembly of inner membrane protein complexes: implications for Barth Syndrome. Mol. Biol. Cell, 2005, 16(11), 5202-5214.
66. Ma, L.; Vaz, F.M.; Gu, Z.; Wanders, R.J.; Greenberg, M.L. The human TAZ gene complements mitochondrial dysfunction in the yeast taz1Delta mutant. Implications for Barth syndrome. J. Biol. Chem., 2004, 279(43), 44394-44399.
67. Khuchua, Z.; Yue, Z.; Batts, L.; Strauss, A.W. A zebrafish model of human Barth syndrome reveals the essential role of tafazzin in cardiac development and function. Circ. Res., 2006, 99(2), 201-208.
68. Xu, Y.; Zhang, S.; Malhotra, A.; Edelman-Novemsky, I.; Ma, J.; Kruppa, A.; Cernicica, C.; Blais, S.; Neubert, T.A.; Ren, M.; Schlame, M. Characterization of tafazzin splice variants from humans and fruit flies. J. Biol. Chem., 2009, 284(42), 29230-29239.
69. McMurray, J.J.; Pfeffer, M.A. Heart failure. Lancet, 2005, 365(9474), 1877-1889.
70. Saini-Chohan, H.K.; Hatch, G.M. Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. Curr. Drug Metab., 2009, 10(3), 206-219.
71. Carraway, J.W.; Park, S.; McCune, S.A.; Holycross, B.J.; Radin, M.J. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. J. Cardiovasc. Pharmacol., 1999, 33(3), 451-460.
72. Sparagna, G.C.; Johnson, C.A.; McCune, S.A.; Moore, R.L.; Murphy, R.C. Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J. Lipid Res., 2005, 46(6), 1196-1204.
73. Chicco, A.J.; Sparagna, G.C. Role of cardiolipin alterations in mitochondrial dysfunction and disease. Am. J. Physiol. Cell. Physiol., 2007, 292(1), C33-44.
74. Acehan, D.; Vaz, F.; Houtkooper, R.H.; James, J.; Moore, V.; Tokunaga, C.; Kulik, W.; Wansapura, J.; Toth, M.J.; Strauss, A.; Khuchua, Z. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome. J. Biol. Chem., 2011, 286(2), 899-908.
75. Soustek, M.S.; Falk, D.J.; Mah, C.S.; Toth, M.J.; Schlame, M.; Lewin, A.S.; Byrne, B.J. Characterization of a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. Hum. Gene Ther., 2011, 22(7), 865-871.
76. Minkler, P.E.; Hoppel, C.L. Separation and characterization of cardiolipin molecular species by reverse-phase ion pair highperformance liquid chromatography-mass spectrometry. J. Lipid Res., 2010, 51(4), 856-865.
77. Phoon, C.K.; Acehan, D.; Schlame, M.; Stokes, D.L.; Edelman-Novemsky, I.; Yu, D.; Xu, Y.; Viswanathan, N.; Ren, M. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction. J. Am. Heart Assoc., 2012, 1(2), 10.1161/JAHA.111.000455. Epub 2012 Apr 24.
78. Kiebish, M.A.; Yang, K.; Liu, X.; Mancuso, D.J.; Guan, S.; Zhao, Z.; Sims, H.F.; Cerqua, R.; Cade, W.T.; Han, X.; Gross, R.W. Dysfunctional cardiac mitochondrial bioenergetic, lipidomic, and signaling in a murine model of Barth syndrome. J. Lipid Res., 2013, 54(5), 1312-1325.
79. Powers, C.; Huang, Y.; Strauss, A.; Khuchua, Z. Diminished Exercise Capacity and Mitochondrial bc1 Complex Deficiency in Tafazzin-Knockdown Mice. Front. Physiol., 2013, 4, 74.
80. Aprikyan, A.A.; Khuchua, Z. Advances in the understanding of Barth syndrome. Br. J. Haematol., 2013, 161(3), 330-338.
81. Rosca, M.; Minkler, P.; Hoppel, C.L. Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim. Biophys. Acta, 2011, 1807(11), 1373-1382.
82. Mulligan, C.M.; Sparagna, G.C.; Le, C.H.; De Mooy, A.B.; Routh, M.A.; Holmes, M.G.; Hickson-Bick, D.L.; Zarini, S.; Murphy, R.C.; Xu, F.Y.; Hatch, G.M.; McCune, S.A.; Moore, R.L.; Chicco, A.J. Dietary linoleate preserves cardiolipin and attenuates mitochondrial dysfunction in the failing rat heart. Cardiovasc. Res., 2012, 94(3), 460-468.
83. Shah, K.B.; Duda, M.K.; O'Shea, K.M.; Sparagna, G.C.; Chess, D.J.; Khairallah, R.J.; Robillard-Frayne, I.; Xu, W.; Murphy, R.C.; Des Rosiers, C.; Stanley, W.C. The cardioprotective effects of fish oil during pressure overload are blocked by high fat intake: role of cardiac phospholipid remodeling. Hypertension, 2009, 54(3), 605-611.
84. Rees, M.L.; Gioscia-Ryan, R.A.; McCune, S.A.; Browder, J.C.; Zachman, D.K.; Chicco, A.J.; Johnson, C.A.; Murphy, R.C.; Moore, R.L.; Sparagna, G.C. The AIN-76A defined rodent diet accelerates the development of heart failure in SHHF rats: A cautionary note on its use in cardiac studies. J. Anim. Physiol. Anim. Nutr. (Berl), 2014, 98(1):56-64.
85. Khairallah, R.J.; Kim, J.; O'Shea, K.M.; O'Connell, K.A.; Brown, B.H.; Galvao, T.; Daneault, C.; Des Rosiers, C.; Polster, B.M.; Hoppel, C.L.; Stanley, W.C. Improved mitochondrial function with diet-induced increase in either docosahexaenoic acid or arachidonic acid in membrane phospholipids. PLoS One, 2012, 7(3), e34402.
86. Chang, W.; Zhang, M.; Li, J.; Meng, Z.; Xiao, D.; Wei, S.; Chen, L.; Wang, C.; Hatch, G.M. Berberine attenuates ischemiareperfusion injury via regulation of adenosine-5'-monophosphate kinase activity in both non-ischemic and ischemic areas of the rat heart. Cardiovasc. Drugs Ther., 2012, 26(6), 467-478.
87. Chang, W.; Zhang, M.; Li, J.; Meng, Z.; Wei, S.; Du, H.; Chen, L.; Hatch, G.M. Berberine improves insulin resistance in cardiomyocytes via activation of 5'-adenosine monophosphate-activated protein kinase. Metabolism, 2013, 62(8), 1159-1167.
88. Piao, L.; Marsboom, G.; Archer, S.L. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J. Mol. Med. (Berl), 2010, 88(10), 1011-1020.
89. Nagendran, J.; Gurtu, V.; Fu, D.Z.; Dyck, J.R.; Haromy, A.; Ross, D.B.; Rebeyka, I.M.; Michelakis, E.D. A dynamic and chamberspecific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. J. Thorac. Cardiovasc. Surg., 2008, 136(1), 168-78, 178. e1-3.
90. Stanley, W.C.; Hoppel, C.L. Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc. Res., 2000, 45(4), 805-806.
91. Jaswal, J.S.; Keung, W.; Wang, W.; Ussher, J.R.; Lopaschuk, G.D. Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta, 2011, 1813(7), 1333-1350.
92. Bayeva, M.; Gheorghiade, M.; Ardehali, H. Mitochondria as a therapeutic target in heart failure. J. Am. Coll. Cardiol., 2013, 61(6), 599-610.
93. Shi, Y. Emerging roles of cardiolipin remodeling in mitochondrial dysfunction associated with diabetes, obesity, and cardiovascular diseases. J. Biomed. Res., 2010, 24(1), 6-15.
94. Monteiro, J.P.; Oliveira, P.J.; Jurado, A.S. Mitochondrial membrane lipid remodeling in pathophysiology: A new target for diet and therapeutic interventions. Prog. Lipid Res., 2013, 52(4), 513-528.
95. Mejia, E.M.; Nguyen, H.; Hatch, G.M. Mammalian cardiolipin biosynthesis. Chem. Phys. Lipids, 2014,179, 11-6.
96. Saini-Chohan, H.K.; Dakshinamurti, S.; Taylor, W.A.; Shen, G.X.; Murphy, R.; Sparagna, G.C.; Hatch, G.M. Persistent pulmonary hypertension results in reduced tetralinoleoyl-cardiolipin and mitochondrial complex II + III during the development of right ventricular hypertrophy in the neonatal pig heart. Am. J. Physiol. Heart Circ. Physiol., 2011, 301(4), H1415-24.